Eli Lilly's Mounjaro weight loss injection has seen a price reduction of nearly 70% in China

Eli Lilly (LLY.US) has significantly reduced the price of the weight loss injection Mounjaro in China. Currently, on the JD.com (09618.HK) platform, the monthly fee for the lowest dosage of Mounjaro has dropped to 599 RMB, nearly 70% lower than the 1,758 RMB price at its launch last year; the price for the highest dosage has also decreased from 4,758 RMB to 1,599 RMB. On Alibaba's (09988.HK) platform, the price after using coupons is even lower.

This decision by Eli Lilly is a response to Novo Nordisk's earlier price reduction actions. It is reported that Novo Nordisk has halved the price of the weight loss injection Wegovy in certain provinces and cities in China. As the core ingredient of Wegovy, Semaglutide, is expected to have its patent expire in March this year, several Chinese pharmaceutical companies are likely to launch low-cost generic drugs, prompting the two multinational giants to actively consolidate their market positions in China